Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 26, 1994 - Issue 6
Submit an article Journal homepage
29
Views
11
CrossRef citations to date
0
Altmetric
Original Article

Comparison of Enhanced Potency Inactivated Poliovirus Vaccine (EIPV) Versus Standard Oral Poliovirus Vaccine (OPV) in Thai Infants

Sriluck Simasathien From the Department of Pediatrics, Phramongkutkloa Hospital, Bangkok, Thailand
,
Sricharoen Migasena Vaccine Trial Centre, Department of Tropical Medicine, Mahidol University, Bangkok, Thailand
,
Coen Beuvery National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands
,
Gijsbert Van Steenis National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands
,
Rudiwilai Samakoses From the Department of Pediatrics, Phramongkutkloa Hospital, Bangkok, Thailand
,
Punnee Pitisuttitham From the Department of Pediatrics, Phramongkutkloa Hospital, Bangkok, Thailand
&
Timo Vesikari Department of Biomedical Sciences, University of Tampere, Tampere, Finland
 show all
Pages 731-738 | Received 05 Jul 1994, Accepted 07 Sep 1994, Published online: 08 Jul 2009

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Juan Li, Zhujiazi Zhang, Herun Zhang, Maozhong Li, Xiaomei Li, Li Lu, Fang Huang & Jiang Wu. (2021) Seroprevalence of poliovirus antibodies before and after polio vaccine switch in 2012 and 2017 in Beijing. Human Vaccines & Immunotherapeutics 17:2, pages 389-396.
Read now
Pauline Verdijk, Nynke Y Rots & Wilfried AM Bakker. (2011) Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Review of Vaccines 10:5, pages 635-644.
Read now

Articles from other publishers (9)

Agustín Ciapponi, Ariel Bardach, Lucila Rey Ares, Demián Glujovsky, María Luisa Cafferata, Silvana Cesaroni & Aikant Bhatti. (2019) Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Cochrane Database of Systematic Reviews 2019:12.
Crossref
Satoko Ohfuji, Kazuya Ito, Motoki Ishibashi, Shizuo Shindo, Yoshio Takasaki, Takashi Yokoyama, Takato Yokoyama, Yuji Yamashita, Keigo Shibao, Takashi Nakano, Tomomi Tsuru, Shin Irie & Yoshio Hirota. (2017) Immunogenicity study to investigate the interchangeability among three different types of polio vaccine. Medicine 96:23, pages e7073.
Crossref
Xavier Sáez-Llorens, Ralf Clemens, Geert Leroux-Roels, José Jimeno, Sue Ann Costa Clemens, William C Weldon, M Steven Oberste, Natanael Molina & Ananda S Bandyopadhyay. (2016) Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. The Lancet Infectious Diseases 16:3, pages 321-330.
Crossref
Concepción F Estívariz, Mark A Pallansch, Abhijeet Anand, Steven GF Wassilak, Roland W Sutter, Jay D Wenger & Walter A Orenstein. (2013) Poliovirus vaccination options for achieving eradication and securing the endgame. Current Opinion in Virology 3:3, pages 309-315.
Crossref
Kimberly M. Thompson, Mark A. Pallansch, Radboud J. Duintjer Tebbens, Steve G. Wassilak, Jong‐Hoon Kim & Stephen L. Cochi. (2013) Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control. Risk Analysis 33:4, pages 516-543.
Crossref
Concepción F Estívariz, Hamid Jafari, Roland W Sutter, T Jacob John, Vibhor Jain, Ashutosh Agarwal, Harish Verma, Mark A Pallansch, Ajit P Singh, Sherine Guirguis, Jitendra Awale, Anthony Burton, Sunil Bahl, Arani Chatterjee & R Bruce Aylward. (2012) Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6–9 months in Moradabad, India: a community-based, randomised controlled trial. The Lancet Infectious Diseases 12:2, pages 128-135.
Crossref
Marie-Claude Bonnet & Anil Dutta. (2008) World wide experience with inactivated poliovirus vaccine. Vaccine 26:39, pages 4978-4983.
Crossref
Katharine Hogg & Geoff Hogg. (2003) The immunogenicity of oral poliomyelitis vaccine in a primary vaccination series at 2, 4 and 6 months given concurrently with Hib, hepatitis B and diphtheria, tetanus and whole-cell pertussis vaccines administered as three separate injections or as a combination pentavalent vaccine. Vaccine 21:21-22, pages 2906-2910.
Crossref
EMMANUEL VIDOR, CARLTON MESCHIEVITZ & STANLEY PLOTKIN. (1997) Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. The Pediatric Infectious Disease Journal 16:3, pages 312-322.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.